Compare IDEXX Laboratories, Inc. (IDXX) vs Noble Corporation plc (NE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs Noble Corporation plc — how do they compare? IDEXX Laboratories, Inc. trades at $569.65 (market cap $46.22B), while Noble Corporation plc trades at $44.15 (market cap $7.10B). The key difference: IDEXX Laboratories, Inc. is far larger — about 6.5× Noble Corporation plc's market cap, and Noble Corporation plc pays a 4.5% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals.
| IDXX | NE | |
|---|---|---|
Market Cap | $46.22B | $7.10B |
Sector | Health | Technology |
52-Week High | $766.68 | $54.37 |
52-Week Low | $526.44 | $26.61 |
Enterprise Value | $47.12B | $8.53B |
Dividend Yield | — | 4.5% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $570.58, down 4.23% over 24 hours, with a bullish technical signal and strong fundamentals. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $4.27 surpassing the $3.94 expectation. Revenue growth remains robust, supported by a 74.21% ROE and expanding diagnostic offerings. Recent news highlights product expansion, including a dual-species cardiac test, reinforcing its market leadership in veterinary diagnostics.
The outlook is positive, driven by durable competitive advantages and international growth potential. However, elevated valuation multiples and competitive pressures pose risks. Analyst consensus is bullish with a $683.33 price target, suggesting significant upside from current levels, though investors should monitor execution on guidance and macroeconomic headwinds.
Noble Corporation (NE) trades at $44.08, up 1.22% on the day, with a bullish technical signal from moving averages. The company reported mixed Q2 2026 results, missing EPS estimates but securing $200 million in new contracts. Revenue and net income are trending lower year-over-year, with a P/E ratio of 47.32 indicating a premium valuation. Recent news highlights multiple law firm investigations into the company.
The outlook is cautious. While a $6.8 billion backlog and consistent dividends provide support, declining profitability, high valuation, and legal scrutiny present significant risks. Analyst consensus is a Hold with a $46.00 price target, suggesting limited near-term upside from current levels amid operational and sentiment headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About Noble Corporation plc
Noble Corporation plc is a leading offshore drilling contractor for the oil and gas industry. The company owns and operates a high-specification fleet of mobile offshore drilling units, including drillships and semi-submersibles, that are used for exploration and production activities in deepwater and harsh environments worldwide. Noble focuses on providing safe, efficient, and reliable drilling services to major and independent oil and gas companies globally.
Read more on NE →
